Full-Time

Lead Data Steward

Posted on 7/10/2026

Deadline 7/19/26
Roche

Roche

1-10 employees

Global pharmaceuticals and diagnostics company

No salary listed

Hyderabad, Telangana, India

In Person

Category
Data & Analytics (1)
Required Skills
Power BI
SQL
Data Engineering
Tableau
Role-based Access Control
Collibra
Alteryx
Data Governance
Snowflake

Get referred to Roche

Find people who can refer or advise you

Requirements
  • You hold a university degree in Information Management, Data Science, Business Analytics, Computer Science, Information Systems, Engineering, Business Administration, Procurement, Finance, or a related field.
  • You have significant 7+ years of experience in data stewardship, data governance, data management, analytics, metadata management, data quality, business analysis, or data product delivery.
  • You have strong understanding of how data moves from source systems into analytical products, dashboards, and business decision-making.
  • You can translate between business definitions, data models, quality rules, access requirements, and downstream reporting needs.
  • You have strong Structured Query Language (SQL) literacy and can investigate data issues, joins, grain, duplicates, mappings, reconciliation gaps, and metric logic.
  • You have experience defining or supporting data dictionaries, business glossaries, metadata, lineage, data quality rules, data ownership, and usage documentation.
  • You are familiar with modern data platforms and tools such as Snowflake, dbt, GitLab, Collibra, Immuta, Tableau, Power BI, Alteryx, or similar technologies.
  • You can operate independently in ambiguous situations, structure complex problems, and drive alignment across business, governance, and technical teams.
  • You have strong stakeholder management skills and can influence teams without direct authority in a global, cross-functional environment.
  • You communicate clearly in English, both verbally and in writing, and can explain complex data topics in simple business language.
Responsibilities
  • Leading data stewardship for priority Global Procurement data products, including business definitions, metric logic, ownership, metadata, lineage, data quality expectations, and approved usage.
  • Defining and maintaining data product standards and data product contracts, including product purpose, data grain, source dependencies, business rules, ownership, service expectations, and release-readiness criteria.
  • Partnering with business owners and domain experts to resolve conflicting metric definitions and align on certified business logic for critical procurement data products.
  • Working with data engineering teams to translate business rules into governed data products using modern data platforms and tools such as Snowflake, dbt, GitLab, and related data engineering practices.
  • Ensuring that production-grade data products are properly documented and registered in enterprise cataloging tools such as Collibra, including technical metadata, business glossary terms, ownership, stewardship, and lineage.
  • Supporting data access and policy alignment in partnership with governance, informatics, and security teams, including Role-Based Access Control (RBAC), Immuta-enabled policy controls, masking requirements, and Personally Identifiable Information (PII) handling where applicable.
  • Leading data quality issue triage for critical data products by identifying root causes, coordinating resolution, tracking open risks, and escalating issues that may impact leadership reporting or business-critical decisions.
  • Helping embed stewardship into the data product lifecycle, including intake, requirements clarification, Definition of Done, change control, release readiness, cataloging, and ongoing product support.
  • Supporting the transition from legacy reporting logic, manual workflows, and dashboard-level calculations into governed, reusable data products.
  • Coaching colleagues and stakeholders on data stewardship practices, business glossary quality, metadata standards, documentation discipline, and responsible data usage.
Desired Qualifications
  • Certification or training in data management, data governance, Snowflake, Collibra, DAMA / Certified Data Management Professional (CDMP), procurement, supply chain, or analytics is a plus.
  • Knowledge of Data Mesh, data product management, data contracts, semantic layers, Findable, Accessible, Interoperable, and Reusable (FAIR) data principles, or enterprise data governance frameworks.
  • Experience with data privacy, security, classification, or access-control requirements in a large global organization.
  • Experience supporting data migration or modernization from legacy reporting environments into governed cloud data platforms.
  • Experience in procurement, supply chain, finance, spend analytics, savings, sourcing, contracts, supplier data, category management, or sustainability data.

Roche is a global leader in pharmaceuticals and diagnostics. It develops medicines and diagnostic tools that help detect, monitor, and treat diseases, using research and biotechnology to drive new therapies and tests. Roche combines drug development with in-house diagnostic products to support personalized medicine, where treatments are tailored to individual patients based on test results. Its approach differs from many peers by integrating drug discovery with diagnostic capabilities and by expanding its research through strategic acquisitions (like Genentech) to strengthen its biotechnology and R&D capabilities. The company’s goal is to improve patient outcomes and healthcare worldwide by delivering reliable medicines, accurate diagnostic tests, and data-driven care.

Company Size

1-10

Company Stage

IPO

Headquarters

Basel, Switzerland

Founded

1896

Get referred to Roche

Find people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Roche targets top-three obesity status by 2030 via CT-388 and petrelintide assets.
  • The $1.5B Poseida acquisition secures off-the-shelf CAR-T therapies for oncology and immunology.
  • AI-driven diagnostics gain traction through the $750M PathAI acquisition closing in 2026 H2.

What critics are saying

  • Kadcyla and Perjeta biosimilar erosion in 2025–2026 will strip billions from oncology revenue.
  • Ocrevus loss of exclusivity in 2029 threatens the entire immunology franchise profitability.
  • Eight cancer drugs face biosimilars by 2030, risking CHF 6.7B sales decline easily.

What makes Roche unique

  • Roche uniquely integrates Pharmaceuticals and Diagnostics under one roof for personalized healthcare.
  • Only Roche combines world-class drug R&D with global diagnostics leadership seamlessly.
  • Roche leverages companion diagnostics to pair targeted therapies with precise patient identification.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Performance Bonus

Company News

Dealroom.co
Apr 16th, 2026
SAGA company information, funding & investors

SAGA, providing cancer companion diagnostic testing of tissue and non-invasive monitoring of circulating tumor dna (ctdna). Here you'll find information about their funding, investors and team.

Yahoo Finance
Apr 13th, 2026
Roche receives CE mark for Elecsys NfL blood test to detect neuroinflammation in multiple sclerosis

Roche has received CE mark approval for its Elecsys Neurofilament Light Chain blood test to detect neuroinflammation in adults with relapsing remitting multiple sclerosis. The test measures NfL, a protein released during nerve cell injury, providing insight into neuroaxonal damage associated with the disease. Multiple sclerosis affects over 2.9 million people worldwide. Whilst early and regular monitoring is critical, patients often struggle to access routine MRI scans. The minimally invasive blood test offers a more accessible alternative, complementing clinical assessments and potentially enabling earlier intervention. The test runs on Roche's widely available cobas instruments, delivering standardised results and requiring only a simple blood sample. This reduces the need for patients to travel to specialist centres, making frequent monitoring more practical where traditional testing faces geographic, financial or logistical barriers.

Bizwatch
Apr 12th, 2026
Roche invests $20M in degrader-antibody conjugate platform via C4 Therapeutics deal worth up to $1B

Roche has partnered with C4 Therapeutics to develop degrader-antibody conjugates (DACs), marking a $20 million upfront payment with potential milestone payments exceeding $1 billion. The collaboration targets cancer therapeutics using C4's Torpedo platform. DACs represent a next-generation approach to antibody-drug conjugates (ADCs). Whilst ADCs attach cytotoxic drugs to antibodies, DACs use targeted protein degradation payloads to selectively eliminate specific proteins within cancer cells, potentially reducing toxicity and drug resistance whilst accessing previously difficult targets. Amongst Korean listed companies, Orum Therapeutics leads DAC development, having licensed ORM-6151 to Bristol Myers Squibb in 2023. Y-Biologics partnered with Ubix Therapeutics, whilst Oscotec is developing three DAC pipelines through subsidiary Genosco, targeting technology transfers after 2028.

Yahoo Finance
Mar 30th, 2026
Roche gets FDA clearance for cobas c703 and ISE neo lab testing units with 2,000 tests per hour

Roche has received FDA 510(k) clearance for its cobas c703 and cobas ISE neo analytical units, designed to enhance laboratory efficiency through increased automation and testing capacity. The units are part of Roche's cobas pro integrated solutions platform. The cobas c703 delivers up to 2,000 tests per hour with 70 reagent positions, doubling clinical chemistry throughput whilst reducing reagent reloads. The cobas ISE neo provides up to 1,800 tests per hour with automated maintenance, reducing hands-on time and plastic waste compared to previous systems. Both units feature monthly operator maintenance to improve uptime and help laboratories address staffing shortages and growing test volumes. Roche has over 4,000 cobas analysers installed across the United States.

Yahoo Finance
Mar 30th, 2026
Roche launches cobas MPX-E assay, 4-in-1 donor screening test for HIV, HCV, HBV and HEV

Roche has launched the cobas MPX-E assay, a four-in-one donor screening test that simultaneously detects HIV, Hepatitis C, B and E viruses. The test is now available in countries accepting the CE mark. The assay consolidates detection of four major viral targets into a single workflow, improving laboratory efficiency and reducing costs. It features dual-target detection for HIV-1 and enhanced sensitivity for Hepatitis E, which causes an estimated 20 million infections and 70,000 deaths annually worldwide. The test runs on Roche's fully automated cobas x800 systems, which process over 10 million tests monthly across laboratories globally. The ready-to-load reagents enable up to eight hours of walk-away time. The nucleic acid testing blood screening market is valued at approximately 800 million Swiss francs globally, with an expected annual growth rate of 2% through 2029.

INACTIVE